SM
IOVA icon

Sabby Management’s Iovance Biotherapeutics IOVA Stock Holding History

Sabby Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-195
Closed -$140K – 191
2017
Q2 		$140K Buy
+195
New +$1.24K 0.01% 190
2017
Q1 		– Sell
-1,260
Closed -$876K – 284
2016
Q4 		$876K Sell
1,260
-6,641
-84% -$45.7K 0.05% 155
2016
Q3 		$6.5M Buy
7,901
+375
+5% +$3.17K 0.24% 64
2016
Q2 		$6.1M Buy
+7,526
New +$47.3K 0.32% 48

Other funds holding IOVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Sabby Management's IOVA Position: Q3 2017 in Review

Sabby Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2017, closing a stake of 71,251 shares — an estimated $524K sold.

Sabby Management first reported a position in IOVA in Q1 2015 and held it in 10 quarters. The position peaked at $4.54M in Q1 2015. 85 funds tracked by Wall St. Rank hold IOVA as of Q3 2017.

  • Sabby Management reported no remaining Iovance Biotherapeutics position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 71,251 Iovance Biotherapeutics shares in Q3 2017, an estimated $524K.
  • Sabby Management first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 10 quarters.
  • Sabby Management's Iovance Biotherapeutics position peaked at $4.54M in Q1 2015.
  • 85 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.